Fundraising Fox
Noveome Biotherapeutics
Pittsburgh, US · Delaware corporation · 5 known investors
Find your way into Noveome Biotherapeutics
Each arrow is one introduction. Sign up to fill in the first one.
127 people can intro you to A.
Ask Susan Orr to introduce you to A. Clarke Atwell
You →Susan · together at Claris Bio →A.
127 people can intro you to Larry
Ask Jamie Chen to introduce you to Larry Brown
You →Jamie · together at Noveome Biotherapeutics →Larry
1 person can intro you to William
Ask Sam Okafor to introduce you to William Golden
You →Sam · together at Noveome Biotherapeutics →William
Sign up to find every way you can get introduced to Noveome Biotherapeutics
- Your email: who you already know at Noveome Biotherapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Noveome Biotherapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Noveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.
Founders & leadership
PW
Patrick WelchExecutive
WG
William GoldenFounder & Chairman2021–2022William Golden holds a Bachelor's degree in Mechanical Engineering from the University of Notre Dame and has prior experience in biotechnology business development and executive roles.
AC
A. Clarke AtwellExecutiveA. Clarke Atwell is an executive officer and director at Noveome Biotherapeutics, a clinical-stage biopharmaceutical company developing ST266 for neuroprotection and tissue healing. He has held leadership roles in biopharmaceutical companies spanning product development, licensing, and commercial operations across multiple therapeutic areas.
LB
Larry BrownChief Scientific OfficerLarry Brown is an executive with experience in large pharmaceutical companies and venture-backed biotech firms, with expertise in drug delivery systems including polymeric microspheres, pulmonary formulations, and injectable systems. He is leading Noveome's clinical development of ST266, a secretome candidate being investigated for neuroprotection and tissue healing applications.
Board
Investors · 5
Also in the syndicate · 4
Highmark Blue Cross/ Blue ShieldLancet CapitalUniversity of PittsburghUPMC Enterprises
Funding
SEC filings, press & company announcements$76M disclosed across 6 of 7 rounds · 2015–2026
- $15MSeries DApr 2019 · 2 sources
Carnegie Mellon University, Highmark Blue Cross/ Blue Shield, Lancet Capital, University of Pittsburgh, UPMC Enterprises
Source ↗
▶$6.8MraisedAug 2026 · 6 investors · BiotechnologyRule 506(b)
▶$6.8MraisedAug 2026 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick WelchExecutive Officer, Director
- Robert LangerDirector
- Ronald PoropatichDirector
- Eric KellerExecutive Officer, Director
- Houman HemmatiDirector
- Craig NemiroffDirector
- Michael KaufmanDirector
- Karin PotokaExecutive Officer
- Larry BrownExecutive Officer
- Offering amount
- $15M
- Amount sold
- $6.8M
- Proceeds to insiders
- $353K
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$36.2MraisedAug 2024 · 66 investors · BiotechnologyRule 506(b)
▶$36.2MraisedAug 2024 · 66 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Michael KaufmanDirector
- Patrick WelchExecutive Officer
- Eric KellerDirector
- Ronald PoropatichDirector
- Craig NemiroffDirector
- Gretchen KraemerExecutive Officer
- Houman HemmatiDirector
- Offering amount
- $51.3M
- Amount sold
- $36.2M
- Proceeds to insiders
- $186K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$870KraisedOct 2020 · 7 investors · BiotechnologyRule 506(b)
▶$870KraisedOct 2020 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- William GoldenExecutive Officer, Director
- Patrick WelchDirector
- Terence GoldenDirector
- Donald WagnerDirector
- Offering amount
- $15M
- Amount sold
- $870K
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedApr 2019 · 39 investors · BiotechnologyRule 506(b)
▶$15MraisedApr 2019 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- John McArthurDirector
- William GoldenExecutive Officer, Director
- Terence GoldenDirector
- Patrick WelchDirector
- Donald WagnerDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedApr 2016 · 39 investors · BiotechnologyRule 506(b)
▶$2.2MraisedApr 2016 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terence GoldenDirector
- John McArthurDirector
- William GoldenExecutive Officer, Director
- Donald WagnerDirector
- A. Clarke AtwellExecutive Officer, Director
- Robert LangerDirector
- Offering amount
- $2.5M
- Amount sold
- $2.2M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Noveome Biotherapeutics went on to found or lead other companies.
Related companies · 5
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Alterome Therapeutics, Inc.Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
NucleomeNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
MyomeMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.
CellanomeCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
Companies working in the same space as Noveome Biotherapeutics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase I | 2012 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $147.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Noveome Biotherapeutics do?
- Noveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.
- Who are Noveome Biotherapeutics's investors?
- Noveome Biotherapeutics's investors include Carnegie Mellon University.
- How much funding has Noveome Biotherapeutics raised?
- Noveome Biotherapeutics has disclosed $76M raised across 6 of its 7 known rounds.
- Where is Noveome Biotherapeutics headquartered?
- Noveome Biotherapeutics is headquartered in Pittsburgh, US.